Home Biotechnology Johnson & Johnson (Innovative Medicine)
J

Johnson & Johnson (Innovative Medicine)

Profile managed by Bizz Id
United States 500+ employees 1886

Description

Johnson & Johnson Innovative Medicine is the pharmaceutical segment of Johnson & Johnson (formerly Janssen). It develops and markets medicines in oncology, immunology, neuroscience, cardiopulmonary and retina; its US headquarters is in Titusville, New Jersey.

Products

15 products
Amivantamab (RYBREVANT FASPRO)

Brand: RYBREVANT FASPRO (amivantamab-vmjw). Oncology.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Amivantamab: see suppliers →

Amivantamab (RYBREVANT)

Brand: RYBREVANT (amivantamab-vmjw). Oncology. In registration: frontline NSCLC with chemotherapy (PAPILLON) and head and neck cancer (ORIGAMI-4); Phase 3: colorectal cancer (ORIGAMI-2, ORIGAMI-3) and head and neck (ORIGAMI-5).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Amivantamab: see suppliers →

Daratumumab

Brand: DARZALEX. Oncology. Partner: Genmab. New indication in registration: frontline transplant-ineligible multiple myeloma (CEPHEUS).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Daratumumab: see suppliers →

Daratumumab + Hyaluronidase

Brand: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj). Oncology. Partners: Genmab (daratumumab), Halozyme (ENHANZE platform).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Daratumumab: see suppliers → · Hyaluronidase: see suppliers →

Epoetin alfa

Brand: PROCRIT. Oncology (per product list).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Epoetin alfa: see suppliers →

Golimumab (SIMPONI ARIA)

Brand: SIMPONI ARIA. Immunology.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Golimumab: see suppliers →

Golimumab (SIMPONI)

Brand: SIMPONI. Immunology.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Golimumab: see suppliers →

Guselkumab

Brand: TREMFYA. Immunology. Partner: MorphoSys. In registration: juvenile psoriatic arthritis; Phase 3: paediatric Crohn's disease (MACARONI-23) and paediatric ulcerative colitis (QUASAR JR).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Guselkumab: see suppliers →

Infliximab

Brand: REMICADE. Immunology.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Infliximab: see suppliers →

Nipocalimab

Brand: IMAAVY (nipocalimab-aahu). Immunology. In registration: warm autoimmune hemolytic anemia (ENERGY); Phase 3: SLE, Sjogren's disease, HDFN, FNAIT; Phase 2: idiopathic inflammatory myopathy.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Nipocalimab: see suppliers →

Pasritamig

Metastatic castration-resistant prostate cancer, Phase 3 (KLK2-comPAS, KLK2-PASenger).

Under development

Finished product (FDF)

Verified on 2026-10-21

Pasritamig: see suppliers →

Ramantamig

R/R multiple myeloma (TRIlogy-4, TRIlogy-5) and transplant-ineligible NDMM with daratumumab (TRIlogy-7), Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ramantamig: see suppliers →

Talquetamab

Brand: TALVEY (talquetamab-tgvs). Oncology. In registration: R/R multiple myeloma (MonumenTAL-3, MonumenTAL-6) and in combination with TECVAYLI (RedirecTT-1, MonumenTAL-6); Phase 3: transplant-ineligible NDMM (MajesTEC-7).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Talquetamab: see suppliers →

Teclistamab

Brand: TECVAYLI (teclistamab-cqyv). Oncology. In registration: MM 1-3 prior lines (MajesTEC-3), R/R MM CD38-exposed (MajesTEC-9) and in combination with TALVEY; Phase 3: NDMM (MajesTEC-4, MajesTEC-7).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Teclistamab: see suppliers →

Ustekinumab

Brand: STELARA. Immunology. New indications in registration: paediatric ulcerative colitis (UNIFI JR) and juvenile psoriatic arthritis (PSUMMIT JR).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ustekinumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free